Related Experiment Videos
Can we make surrogate beta-cells better than the original?
1Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, One Joslin Place, Boston, MA 02215, USA. gordon.weir@joslin.harvard.edu
Seminars in Cell & Developmental Biology
|May 6, 2004
Summary
Diabetes stems from insufficient pancreatic beta-cell mass, driving the need for cell replacement therapy. New cell sources and bioengineering strategies are crucial for overcoming transplantation challenges and meeting patient demand.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Bioengineering
Background:
- Insufficient pancreatic beta-cell mass is central to type 1 and type 2 diabetes pathogenesis.
- Current islet isolation methods from organ donors are insufficient to meet therapeutic demands.
Purpose of the Study:
- To explore alternative sources for insulin-producing cells for diabetes therapy.
- To investigate bioengineering strategies to enhance cell transplantation outcomes.
Main Methods:
- Review of potential cell sources: embryonic stem cells (ESC), adult stem/precursor cells, transdifferentiation, and xenodonation.
- Discussion of bioengineering approaches to improve cell function and survival post-transplantation.
Main Results:
- Identified multiple promising avenues for generating insulin-producing cells beyond traditional islet isolation.
- Highlighted bioengineering techniques to mitigate transplantation barriers like hypoxia, inflammation, and immune rejection.
Conclusions:
- Developing new sources of beta-cells is essential for effective diabetes cell replacement therapy.
- Bioengineering offers critical strategies to enhance the viability and efficacy of transplanted cells.